Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP770641.RAVAkSoUABwXAhQ4oIXY_-ad6F4GsbTaIg5BtcfN3IPkA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP770641.RAVAkSoUABwXAhQ4oIXY_-ad6F4GsbTaIg5BtcfN3IPkA130_assertion type Assertion NP770641.RAVAkSoUABwXAhQ4oIXY_-ad6F4GsbTaIg5BtcfN3IPkA130_head.
- NP770641.RAVAkSoUABwXAhQ4oIXY_-ad6F4GsbTaIg5BtcfN3IPkA130_assertion description "[In patients with cancers of the infiltrating type, at stage T3-T4, with vessel invasion, lymphatic metastasis, hepatic, or peritoneal metastasis, the positive expression rates of MMP-9 mRNA, VEGF protein, and CD34 were significantly higher than those for patients with tumors of the expanding type (P < 0.01), at stage T1-T2 (P < 0.01), with nonvessel invasion (P < 0.05), without lymphatic metastasis (P < 0.05), and without hepatic (P < 0.001) or peritoneal metastasis (P < 0.001), respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP770641.RAVAkSoUABwXAhQ4oIXY_-ad6F4GsbTaIg5BtcfN3IPkA130_provenance.
- NP770641.RAVAkSoUABwXAhQ4oIXY_-ad6F4GsbTaIg5BtcfN3IPkA130_assertion evidence source_evidence_literature NP770641.RAVAkSoUABwXAhQ4oIXY_-ad6F4GsbTaIg5BtcfN3IPkA130_provenance.
- NP770641.RAVAkSoUABwXAhQ4oIXY_-ad6F4GsbTaIg5BtcfN3IPkA130_assertion SIO_000772 21089052 NP770641.RAVAkSoUABwXAhQ4oIXY_-ad6F4GsbTaIg5BtcfN3IPkA130_provenance.
- NP770641.RAVAkSoUABwXAhQ4oIXY_-ad6F4GsbTaIg5BtcfN3IPkA130_assertion wasDerivedFrom befree-20150227 NP770641.RAVAkSoUABwXAhQ4oIXY_-ad6F4GsbTaIg5BtcfN3IPkA130_provenance.
- NP770641.RAVAkSoUABwXAhQ4oIXY_-ad6F4GsbTaIg5BtcfN3IPkA130_assertion wasGeneratedBy ECO_0000203 NP770641.RAVAkSoUABwXAhQ4oIXY_-ad6F4GsbTaIg5BtcfN3IPkA130_provenance.